Nanoengineering Apolipoprotein A1-Based Immunotherapeutics

David P. Schrijver, Anne de Dreu, Stijn R. J. Hofstraat, Ewelina Kluza, Robby Zwolsman, Jeroen Deckers, Tom Anbergen, Koen de Bruin, Mirre M. Trines, Eveline G. Nugraha, Floor Ummels, Rutger J. Röring, Thijs J. Beldman, Abraham J. P. Teunissen, Zahi A. Fayad, Roy van der Meel, Willem J.M. Mulder (Corresponding author)

Research output: Contribution to journalArticleAcademicpeer-review

4 Citations (Scopus)
145 Downloads (Pure)


In the slipstream of targeting the adaptive immune system, innate immunotherapy strategies are being developed. In this context, technologies based on natural carrier vehicles that inherently interact with the innate immune system, are increasingly being considered. Immunoregulatory nanotherapeutics based on natural apolipoprotein A1 (apoA1) are discussed here. This protein is a helical, amphipathic macromolecule and the main constituent of high-density lipoprotein. In that capacity, apoA1 interacts specifically with innate immune cells, such as monocytes and macrophages, to collect and transport lipophilicmolecules throughout the body. Exactly these unique features make apoA1 a compelling elementary constituent of biocompatible self-assembled nanotherapeutics. Such apoA1-based nanotherapeutics (A1-nanotherapeutics) can be engineered and functionalized to induce or mitigate an innate immune response or to orchestrate an adaptive immune response through antigen delivery to dendritic cells. The authors first discuss apoA1's properties and how these can be exploited to generate libraries of A1-nanotherapeutics using advanced manufacturing approaches such as microfluidics or continuous flow methods. Using high-throughput in vitro screening methods and in vivo imagingto identify promising formulations are then recommend. Finally, Three distinct immunotherapy strategies are proposed to effectively treat a variety of diseases—including cancer, infection, and cardiovascular disease—and promote allograft survival in transplantation.

Original languageEnglish
Article number2100083
Number of pages16
JournalAdvanced Therapeutics
Issue number8
Early online date19 Jun 2021
Publication statusPublished - Aug 2021

Bibliographical note

Publisher Copyright:
© 2021 The Authors. Advanced Therapeutics published by Wiley-VCH GmbH


  • apolipoprotein A1
  • immunoengineering
  • immunotherapy
  • nanomedicine
  • nanotherapeutics
  • trained immunity


Dive into the research topics of 'Nanoengineering Apolipoprotein A1-Based Immunotherapeutics'. Together they form a unique fingerprint.

Cite this